CasLoc logo
All Cases PTAB Litigations UPC Oppositions

AstraZeneca LP v. Amneal Pharmaceuticals LLC

1:15-cv-01056

Overview

Case Number 1:15-cv-01056
Filing Date 2015-11-16
Status Terminated
Termination Date 2018-11-29
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:0145
Jury Demand None

Parties

Defendant

Amneal Pharmaceuticals Co. India Private Limited NPE (University / Research)

Represented By

3 Attorneys Listed

Robert M. Vrana

Young, Conaway, Stargatt & Taylor LLP

Tel: +1 (302) 571-6600

Rodney Square, 1000 North King Street

Anne Shea Gaza

Young, Conaway, Stargatt & Taylor LLP

Tel: +1 (302) 571-6727

Rodney Square, 1000 North King Street

Karen L. Pascale

Young, Conaway, Stargatt & Taylor LLP

Tel: +1 (302) 571-6600

Rodney Square, 1000 North King Street

Amneal Pharmaceuticals of New York, LLC Operating Company

Represented By

5 Attorneys Listed

Robert M. Vrana

Young, Conaway, Stargatt & Taylor LLP

Tel: +1 (302) 571-6600

Rodney Square, 1000 North King Street

Loren G. Rene

Email: lrene@winston.com

John R. McNair

Email: jmcnair@winston.com

Anne Shea Gaza

Young, Conaway, Stargatt & Taylor LLP

Tel: +1 (302) 571-6727

Rodney Square, 1000 North King Street

Karen L. Pascale

Young, Conaway, Stargatt & Taylor LLP

Tel: +1 (302) 571-6600

Rodney Square, 1000 North King Street

Amneal Pharmaceuticals LLC Operating Company

Represented By

5 Attorneys Listed

Robert M. Vrana

Young, Conaway, Stargatt & Taylor LLP

Tel: +1 (302) 571-6600

Rodney Square, 1000 North King Street

Loren G. Rene

Email: lrene@winston.com

John R. McNair

Email: jmcnair@winston.com

Anne Shea Gaza

Young, Conaway, Stargatt & Taylor LLP

Tel: +1 (302) 571-6727

Rodney Square, 1000 North King Street

Karen L. Pascale

Young, Conaway, Stargatt & Taylor LLP

Tel: +1 (302) 571-6600

Rodney Square, 1000 North King Street

Plaintiff

AstraZeneca Pharmaceuticals LP NPE (Individual / Inventor)

Represented By

3 Attorneys Listed

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Benjamin A. Smyth

McCarter & English, LLP

Tel: +1 (302) 984-6300

Renaissance Centre, 405 N. King Street, 8th Floor

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

AstraZeneca UK Limited NPE (University / Research)

Represented By

3 Attorneys Listed

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Benjamin A. Smyth

McCarter & English, LLP

Tel: +1 (302) 984-6300

Renaissance Centre, 405 N. King Street, 8th Floor

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

AstraZeneca AB NPE (Individual / Inventor)

Represented By

3 Attorneys Listed

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Benjamin A. Smyth

McCarter & English, LLP

Tel: +1 (302) 984-6300

Renaissance Centre, 405 N. King Street, 8th Floor

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

AstraZeneca LP NPE (Individual / Inventor)

Represented By

6 Attorneys Listed

Ryan P. O'Quinn

Email: oquinnr@finnegan.com

Mark J. Feldstein

Email: mark.feldstein@finnegan.com

Jill K. MacAlpine

Email: jill.macalpine@finnegan.com

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Benjamin A. Smyth

McCarter & English, LLP

Tel: +1 (302) 984-6300

Renaissance Centre, 405 N. King Street, 8th Floor

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 2 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts 8 proceedings
🏛️
USPTO PTAB Trials Counterparts in force
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (2): 🇺🇸 US 🌐 PCT
Parallel Proceedings Across Jurisdictions (8 found):
U.S. Courts: 8
U.S. District Court 2016-05-09
1:16-cv-00338

AstraZeneca LP v. Watson Laboratories Inc.

Asserted Patent
Status: DED
U.S. District Court 2015-11-16
1:15-cv-01057

AstraZeneca LP v. Prinston Pharmaceutical Inc.

Asserted Patent
Status: DED
U.S. District Court 2015-11-16
1:15-cv-01058

AstraZeneca LP v. Apotex Inc.

Asserted Patent
Status: DED
U.S. District Court 2015-11-04
1:15-cv-01013

AstraZeneca LP v. Micro Labs Limited

U.S. Family Sibling (["US8425934"])
Status: DED
U.S. District Court 2015-10-30
1:15-cv-01001

AstraZeneca LP v. InvaGen Pharmaceuticals Inc.

Asserted Patent
Status: DED
U.S. District Court 2015-10-30
1:15-cv-01002

AstraZeneca LP v. Watson Laboratories, Inc.

U.S. Family Sibling (["US8425934"])
Status: DED
U.S. District Court 2015-10-30
1:15-cv-01003

AstraZeneca LP v. Alembic Pharmaceuticals LTD

U.S. Family Sibling (["US8425934"])
Status: DED
U.S. District Court 2015-10-30
1:15-cv-01000

AstraZeneca LP v. Mylan Pharmaceuticals Inc.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

5 Patents

There are 5 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US6251910
1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists
Filed: 1998-07-15
Issued: 2001-06-26
Expired (Term Ended)
Expires: 2018-07-15
US6525060
Triazolo(4,5-d)pyrimidine compounds
Filed: 1999-12-02
Issued: 2003-02-25
Expired (Term Ended)
Expires: 2019-12-02
US7250419
Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition
Filed: 2005-09-21
Issued: 2007-07-31
Expired (Term Ended)
Expires: 2025-09-21
US7265124
Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound
Filed: 2005-10-03
Issued: 2007-09-04
Expired (Term Ended)
Expires: 2021-07-09
US8425934
Pharmaceutical compositions
Filed: 2007-08-20
Issued: 2013-04-23
Active (3.4 yrs remaining) +971d PTA
Expires: 2030-04-17

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Statutorily Barred

Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term — No obviousness-type double patenting truncation noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

3

Dispositive

0

Granted

0

Denied

0

Pending / Review

2

Motions by Category

Procedural / Extension Motion 2 Claim Construction / Markman Filing 1

Key Dispositive Motions & Rulings

Claim Construction / Markman Filing Pending / Under Review
SCHEDULING ORDER: Case referred to the Magistrate Judge for the purpose of exploring ADR. The above-captioned actions are hereby consolidated for all discovery ...
Entry #26 • 2016-02-25 Document →
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME for Defendants Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, and Amneal Pharmaceuticals Co. India Private Limi...
Entry #12 • 2015-12-01 Document →
Procedural / Extension Motion Pending
SO ORDERED, re 12 STIPULATION TO EXTEND TIME for Defendants Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, and Amneal Pharmaceuticals Co. ...
Entry #— • 2015-12-01

Docket Entries

(48 total)
Pleading / Complaint

COMPLAINT filed against Amneal Pharmaceuticals Co. India Private Limited, Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1827902) - filed by AstraZeneca LP, AstraZeneca UK Limited, AstraZeneca Pharmaceuticals LP, AstraZeneca AB. (Attachments: # 1 Exhibit A, # 2 Exhibit B-E, # 3 Civil Cover Sheet)(klc) (Entered: 11/16/2015)

Entry #1 • 2015-11-16
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (klc) (Entered: 11/16/2015)

Entry #2 • 2015-11-16
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: No earlier than October 5, 2015. Date of Expiration of Patent: SEE ANDA FORM.Thirty Month Stay Deadline: No earlier than January 20, 2019. (klc) (Entered: 11/16/2015)

Entry #3 • 2015-11-16
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Numbers: 6,251,910; 6,525,060; 7,250,419; 7,265,124; 8,425,934. (klc) (Entered: 11/16/2015)

Entry #4 • 2015-11-16
1

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent AstraZeneca PLC for AstraZeneca AB - filed by AstraZeneca AB. (klc) (Entered: 11/16/2015)

Entry #5 • 2015-11-16
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc